Porphyrias: A 2015 update.
暂无分享,去创建一个
Laurent Gouya | Hervé Puy | J. Deybach | L. Gouya | H. Puy | Z. Karim | G. Nicolas | Gael Nicolas | S. Lyoumi | Jean-Charles Deybach | Zoubida Karim | Said Lyoumi
[1] M. Laguno,et al. Treatment of chronic hepatitis with boceprevir leads to remission of porphyria cutanea tarda , 2014, The British journal of dermatology.
[2] T. Lefèbvre,et al. Comprehensive cytochrome P450 CYP1A2 gene analysis in French caucasian patients with familial and sporadic porphyria cutanea tarda , 2012, The British journal of dermatology.
[3] E. Marchesini,et al. Long‐term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria , 2015, The British journal of dermatology.
[4] J. Phillips,et al. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda , 2007, Proceedings of the National Academy of Sciences.
[5] P. Harper,et al. High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria , 2013, Journal of Inherited Metabolic Disease.
[6] S. Sandberg,et al. European specialist porphyria laboratories: diagnostic strategies, analytical quality, clinical interpretation, and reporting as assessed by an external quality assurance program. , 2011, Clinical chemistry.
[7] P. Bauer,et al. Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias. , 2015, Journal of hepatology.
[8] S. Ducamp,et al. Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP). , 2013, Human molecular genetics.
[9] M. Badminton,et al. Liver transplantation as a cure for acute intermittent porphyria , 2004, The Lancet.
[10] D. Bissell,et al. Role of delta-aminolevulinic acid in the symptoms of acute porphyria. , 2015, The American journal of medicine.
[11] S. Sandberg,et al. The incidence of inherited porphyrias in Europe , 2013, Journal of Inherited Metabolic Disease.
[12] P. Beaune,et al. Urinary metabolic fingerprint of acute intermittent porphyria analyzed by (1)H NMR spectroscopy. , 2014, Analytical chemistry.
[13] Ó. Pozo,et al. Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study , 2014, Orphanet Journal of Rare Diseases.
[14] J. Deybach,et al. High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. , 2015, Kidney international.
[15] P. Reynier,et al. Pro-oxidant effect of ALA is implicated in mitochondrial dysfunction of HepG2 cells. , 2014, Biochimie.
[16] J. Deybach,et al. La protoporphyrie érythropoïétique : une maladie, deux gènes et trois mécanismes moléculaires , 2010 .
[17] S. Kersten,et al. Peroxisome proliferator-activated receptor alpha controls hepatic heme biosynthesis through ALAS1. , 2009, Journal of molecular biology.
[18] H. Puy,et al. Ursodesoxycholic acid and heme-arginate are unable to improve hematopoiesis and liver injury in an erythropoietic protoporphyria mouse model. , 2006, Physiological research.
[19] A. Singal,et al. Liver transplantation in the management of porphyria , 2014, Hepatology.
[20] G. Elder. 88 – Porphyria Cutanea Tarda and Related Disorders , 2003 .
[21] H. Bonkovsky,et al. Loss-of-Function Ferrochelatase and Gain-of-Function Erythroid-Specific 5-Aminolevulinate Synthase Mutations Causing Erythropoietic Protoporphyria and X-Linked Protoporphyria in North American Patients Reveal Novel Mutations and a High Prevalence of X-Linked Protoporphyria , 2013, Molecular Medicine.
[22] P. Ponka. Cell biology of heme. , 1999, The American journal of the medical sciences.
[23] C. Beaumont,et al. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. , 2011, Blood.
[24] M. Badminton,et al. The cutaneous porphyrias. , 2014, Dermatologic clinics.
[25] A. Finlay,et al. A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases , 2012, The British journal of dermatology.
[26] J. Alpert,et al. A bridge too far: a critique of the new ACGME duty hour requirements. , 2012, The American journal of medicine.
[27] M. Worwood,et al. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. , 2007, Blood.
[28] C. Beaumont,et al. Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model. , 2011, Gastroenterology.
[29] H. Bonkovsky,et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. , 2014, The American journal of medicine.
[30] C. Beaumont,et al. Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. , 2007, Blood.
[31] M. Katze,et al. Down-regulation of hepcidin in porphyria cutanea tarda. , 2008, Blood.
[32] P. Harper,et al. Combined liver and kidney transplantation in acute intermittent porphyria , 2009, Transplant international : official journal of the European Society for Organ Transplantation.
[33] S. Kersten,et al. ' s personal copy Peroxisome Proliferator-Activated Receptor α Controls Hepatic Heme Biosynthesis Through ALAS 1 , 2009 .
[34] Joanne,et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. , 2008, American journal of human genetics.
[35] J. Deybach,et al. Erythropoietic protoporphyria , 2009, Orphanet journal of rare diseases.
[36] S. Ducamp,et al. Late-onset X-linked dominant protoporphyria: an etiology of photosensitivity in the elderly. , 2013, The Journal of investigative dermatology.
[37] V. Desquiret-Dumas,et al. Acute intermittent porphyria causes hepatic mitochondrial energetic failure in a mouse model. , 2014, The international journal of biochemistry & cell biology.
[38] P. Harper,et al. Hepatocyte Transplantation Ameliorates the Metabolic Abnormality in a Mouse Model of Acute Intermittent Porphyria , 2014, Cell transplantation.
[39] C. Lim,et al. Porphomethene inhibitor of uroporphyrinogen decarboxylase: analysis by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. , 2007, Biomedical chromatography : BMC.
[40] Dieter Jahn,et al. Structure and function of enzymes in heme biosynthesis , 2010, Protein science : a publication of the Protein Society.
[41] R. Deulofeu,et al. Increased serum hepcidin levels in patients with porphyria cutanea tarda , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[42] M. Lalanne,et al. Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria , 2013, Proceedings of the National Academy of Sciences.
[43] X. Schneider-Yin,et al. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria , 2015, Expert review of clinical pharmacology.
[44] P. Harper,et al. Porphyrins, porphyrin metabolism and porphyrias. II. Diagnosis and monitoring in the acute porphyrias. , 2000, Scandinavian journal of clinical and laboratory investigation.
[45] H. Heimpel,et al. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations , 2011, Human mutation.
[46] G. Murphy. Diagnosis and management of the erythropoietic porphyrias , 2003, Dermatologic therapy.
[47] D. Richardson,et al. Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol , 2010, Proceedings of the National Academy of Sciences.
[48] H. Bonkovsky,et al. Clinically Important Features of Porphyrin and Heme Metabolism and the Porphyrias , 2014, Metabolites.
[49] C. Ged,et al. 87 – Congenital Erythropoietic Porphyria , 2003 .
[50] C. Beaumont,et al. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. , 2006, American journal of human genetics.
[51] P. Ponka,et al. Iron overload in human disease. , 2012, The New England journal of medicine.
[52] E. Innala,et al. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15‐year follow‐up in northern Sweden , 2011, Journal of internal medicine.
[53] H. Puy,et al. Role of two nutritional hepatic markers (insulin‐like growth factor 1 and transthyretin) in the clinical assessment and follow‐up of acute intermittent porphyria patients , 2009, Journal of internal medicine.
[54] R. Desnick,et al. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice , 2014, Proceedings of the National Academy of Sciences.
[55] G. Song,et al. Liver transplantation for acute-on-chronic liver failure from erythropoietic protoporphyria , 2012, Clinical and Molecular Hepatology.
[56] R. Desnick,et al. Molecular Expression and Characterization of Erythroid-Specific 5-Aminolevulinate Synthase Gain-of-Function Mutations Causing X-Linked Protoporphyria , 2013, Molecular Medicine.
[57] J. Deybach,et al. Hepatocellular carcinoma without cirrhosis: think acute hepatic porphyrias and vice versa , 2011, Journal of internal medicine.
[58] M. F. Stewart,et al. Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance. , 2009, The Journal of investigative dermatology.
[59] S. Thunell. Porphyrins, porphyrin metabolism and porphyrias. I. Update , 2000, Scandinavian journal of clinical and laboratory investigation.
[60] H. Bonkovsky,et al. Hepatitis C, porphyria cutanea tarda and liver iron: an update , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[61] D. Freeman,et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[62] Jiandie D. Lin,et al. Nutritional Regulation of Hepatic Heme Biosynthesis and Porphyria through PGC-1α , 2005, Cell.
[63] C. Handschin,et al. Identification of the xenosensors regulating human 5-aminolevulinate synthase , 2004, Proceedings of the National Academy of Sciences of the United States of America.